Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

TYPE OF SARCOMA: Dermatofirbrosarcoma Protuberans
DRUG: Gleevec (Imatinib Mesylate)
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Scott Schuetze, MD, PhD
University of Michigan

CLINICALTRIALS.GOV IDENTIFIER: NCT00243191

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

IMPACT STATEMENT:
SARC004 sought to collect dermatofibrosarcoma protuberans samples before and during treatment with imatinib to investigate early changes in activity of platelet-derived growth factor receptors and other key signaling molecules. The trial determined that tumor biopsy for sample collection before and during treatment was safe for patients. Paired tumor samples have been collected for advanced proteomic analysis.

To learn more about this study or to contact the study research staff:

Back to top